The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks
Based on the CRL, the STARGLO data do not provide sufficient evidence to support the proposed second-line DLBCL indication in the US patient population
FDA requests Sarepta Therapeutics to suspend distribution of Elevidys and places clinical trials on hold for multiple gene therapy products following 3 deaths
Clinical data showing unprecedented remission rates in newly diagnosed AML patients support advancing ICT01 into pivotal trials
There is a significant unmet medical need for antidepressants that are effective, rapid onset of action and to be well tolerated
Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
Capricor’s BLA for Deramiocel received Priority Review in March 2025
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally
The UK authorization is based on positive results from the Phase III OASIS-1, -2, and -3 trials
Subscribe To Our Newsletter & Stay Updated
